Hims & Hers Health Inc

Hims & Hers stock surges 10% ahead of May 11 earnings, analysts expect $0.03 EPS and a post‑earnings range of $22–$30, driving growth in telehealth & pharma partnerships.

Hims & Hers stock soars 30% after FDA peptideregulation lift, BPC‑157 boost and Bank of America upgrade—telehealth’s next growth engine revealed.

Hims & Hers shares jump 7% after settling with Novo Nordisk to sell Wegovy and Ozempic, boosting its weight‑loss arm and analyst upgrades – but oil‑price volatility cautions investors.

Hims & Hers Health partners with Novo Nordisk to distribute weight‑loss meds via its telehealth platform, sparking a 20% stock surge and new growth prospects.

Hims & Hers partners with Novo Nordisk to distribute Wegovy, boosting its health‑tech reach, stock, and investor confidence amid FDA scrutiny and a 40% share surge.

Hims & Hers stock drops 70% after FDA pulls its copy‑cat weight‑loss drug and Novo Nordisk sues for patent infringement, exposing the company’s legal and growth risks.

Hims & Hers Health’s latest investor moves, ETF yields, and platform growth reveal a robust telehealth trajectory despite short‑seller focus.

Hims & Hers faces rapid growth and regulatory hurdles—its tech‑driven telehealth platform expands globally, but the SAFE Drugs Act threatens its high‑margin weight‑loss line.

Hims & Hers Health, Inc. is facing a crisis of confidence and capital, with analysts warning of margin erosion, governance concerns, and strategic missteps that threaten the company’s valuation and viability.

Hims & Hers Health Inc. (HIMS) is experiencing a surge in investor interest and strategic realignment, driven by leadership changes, global initiatives, and technological collaborations, positioning the company for potential upside in the near futur…